Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-Line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2014
At a glance
- Drugs Lonaprisan (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare
- 05 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 05 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2010 Planned end date changed from Jul 2011 to Apr 2011 as reported by ClinicalTrials.gov.